Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (JPRN-jRCT2031250357) titled '[M25-713]A Phase 2/3 Study of Telisotuzumab Adizutecan Versus SOC After Progression on a Third-Generation EGFR TKI' on Sept. 10.
Study Type: Interventional
Study Design:
randomized controlled trial, open(masking not used), dose comparison control, parallel assignment, treatment purpose
Primary Sponsor: Kenji Sawa
Condition:
Non-Squamous Non-Small Cell Lung Cancer
Intervention:
Phase2
Drug: ABBV-400 Intravenous Infusion (Dose A)
Drug: ABBV-400 Intravenous Infusion (Dose B)
Phase3
Drug: ABBV-400 Intravenous Infusion (Recommended Phase 3 Dose)
Drug: Standard of Care
Recruitment Status: Not Recruiting
P...